Clinical Research on the Effect of Different Extents of Internal Limiting Membrane Peeling on Macular Hole Closure and Visual Acuity

January 13, 2019 updated by: Xiangtian Zhou, Wenzhou Medical University
Observing and describing the surgical effects of different extents of internal limiting membrane peeling combined with internal limiting membrane insertion for macular hole

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Clear diagnosis of macular hole;
  • The minimum diameter of the macular hole is >400 μm;
  • Without serious systemic disease that make patients can not be operated;

Exclusion Criteria:

  • suffering from severe retinal diseases such as: diabetic retinopathy, age-related macular degeneration, peripheral retinal detachment, PVR, etc.;
  • opacitas in the refractive medium can not perform Angio-OCT and visual acuity examination;
  • eye acute and chronic inflammation, such as acute contagious conjunctivitis, acute and chronic keratitis, acute dacryocystitis;
  • traumatic macular hole, secondary macular hole, high myopia macular hole, etc.;
  • having a history of vitrectomy surgery;
  • glaucoma in stage of preclinical, severe stenosis or closure;

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Large extent of ILM Peeling
Extent of ILM peeling is 4DD and the ILM flap is inserted
The extent of ILM peeling is 4DD
Experimental: Small extent of ILM Peeling
Extent of ILM peeling is 2DD and the ILM flap is inserted
The extent of ILM peeling is 2DD

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Condition of postoperative healing of macular holes
Time Frame: 1 year
postoperative photograph of macular retina scanned by Angiography Optical Coherence Tomography(AngioOCT)
1 year
Mean change from baseline in best-corrected visual acuity (BCVA)
Time Frame: 1 year
Assessed using the ETDRS protocol
1 year
change from baseline in foveal avascular zone (FAZ) areas and diameter
Time Frame: 1 year
Assessed on AngioOCT
1 year
change from baseline in the area and diameter of deteriorated circulation zone in superficial and deep retina vessels
Time Frame: 1 year
Assessed on AngioOCT
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Zongduan Zhang, M.D,PhD, The Eye Hospital of Wenzhou Medical University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

February 1, 2019

Primary Completion (Anticipated)

November 1, 2019

Study Completion (Anticipated)

January 31, 2020

Study Registration Dates

First Submitted

January 13, 2019

First Submitted That Met QC Criteria

January 13, 2019

First Posted (Actual)

January 16, 2019

Study Record Updates

Last Update Posted (Actual)

January 16, 2019

Last Update Submitted That Met QC Criteria

January 13, 2019

Last Verified

January 1, 2019

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • ZZD-Macular Hole

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Macular Holes

Clinical Trials on Large extent of ILM Peeling

Subscribe